Characterizing nocturia among Belgian healthy postmenopausal women: Prevalence, degree of bother, etiology and risk factors for nocturia

Pauwaert, Kim; Goessaert, An-Sofie; Ghijselings, Lynn; Bower, Wendy; Depypere, Herman; Everaert, Karel

doi:10.1016/j.maturitas.2020.08.008

Cited by 6 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few studies have explicitly described the prevalence of nocturia in a peri-and postmenopausal population, with precise estimates varying widely based on study population characteristics and the specific diagnostic criteria employed for nocturia [13][14][15][16]. However, genitourinary symptoms attributed to the menopause (i.e., "genitourinary syndrome of menopause") have been reported to occur in nearly 90% of postmenopausal women, and nocturia is one of the most common symptoms in such patients [11].…”

Section: Epidemiologymentioning

confidence: 99%

“…Nakagawa et al reported age, body mass index (BMI), waist-to-hip ratio, blood pressure, cardio-ankle vascular index, depression, difficulty initiating sleep, and non-restorative sleep to be potential risk factors for nocturia in postmenopausal women [3]. In a Belgian cohort of postmenopausal women, waist circumference, sleep onset insomnia, secondary insomnia, and urgency were identified as risk factors for developing nocturia [16].…”

Section: Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

Nocturia through the menopausal transition and beyond: a narrative review

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction and hypothesis Nocturia, defined as the act of waking to pass urine during sleeping, is a common problem in older women and is associated with significant morbidity and impairments in health-related quality of life. The aim of this review was to synthesize the current evidence regarding the incidence, impact, pathophysiology, and specific diagnostic approach of nocturia in the postmenopausal population. Methods We searched PubMed and Web of Science databases to identify relevant studies published through June 2020. Reference lists of the reviews obtained were screened for other articles deemed pertinent by the authors. Results Genitourinary symptoms attributed to the menopause have been reported to occur in nearly 90% of postmenopausal women, and nocturia is one of the most common. The relative deficiency in endogenous estrogen production after the menopause is thought to exacerbate all major pathophysiological mechanisms that may underlie nocturia, including reduced bladder capacity, nocturnal polyuria, global polyuria, and sleep disorders. Diminished estrogen may induce anatomical and physiological bladder changes, contributing to a reduction in functional bladder capacity. Excess nocturnal urine production can also be provoked by estrogen depletion, either via free water-predominant diuresis by an impaired secretion of antidiuretic hormone, or a salt-predominant diuresis owing to diminished activation of the renin-angiotensin-aldosterone axis. Additionally, a relationship between the transition to menopause and impaired sleep has been described, mediated by increased incidence in vasomotor symptoms and obstructive sleep apnea signs during the menopause. Conclusion Further research is necessary to better characterize and manage nocturia in postmenopausal women.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

Nocturia through the menopausal transition and beyond: a narrative review

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Night-time micturition, called nocturia, is a common problem that unfavourably influences both sleep and life quality [ 1 ]. The International Continence Society defines nocturia as urinating once or several times during the night [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Bryophyllum pinnatum and Improvement of Nocturia and Sleep Quality in Women: A Multicentre, Nonrandomised Prospective Trial

Mirzayeva

Forst

Passweg

et al. 2023

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Nocturia is a pathologic condition that significantly affects the quality of sleep. The aetiology of nocturia is multifactorial, and the evidence available on its management remains limited. Besides behavioural measures, validated pharmaceutical treatment options exist but are, however, associated with marked side effects. Prospective clinical studies with tablets prepared from the leaf press juice of the plant Bryophyllum pinnatum revealed a tendency towards reduction of micturition in patients with overactive bladder (OAB) and several improvements in sleep quality. These observations are in part supported by in vitro and in vivo data. In the present study, we investigated the effectiveness of Bryophyllum 50% chewable tablets in the treatment of nocturia and associated sleep disorders. Altogether, 49 women with idiopathic OAB and nocturia of ≥2 voids/night were treated with Bryophyllum 50% tablets for 3 weeks (350 mg chewable tablets, dosage 0-0-2-2 oral tablets; WELEDA AG, Arlesheim, Switzerland). Nocturia, voiding volumes at night (ml), quality of life, sleep quality, and daily sleepiness were assessed before and after treatment with a 3-day micturition diary, the International Consultation on Incontinence evaluating overactive bladder and related impact on quality of life (QoL) [ICIQ-OAB], the Pittsburgh Sleep Quality Index (PSQI), and the Epworth Sleepiness Scale (ESS), respectively. The age of the study population was 68.5 ± 11.6 y. After treatment, nocturia diminished from 3.2 ± 1.4 to 2.3 ± 1.3 ( P < 0.001 ) and the PSQI score decreased from 7.7 ± 3.7 to 6.6 ± 3.4 ( P = 0.004 ). Urgency, the ICIQ score, and the ESS lowered significantly, and the micturition volume showed a tendency to increase. No serious adverse drug reactions were reported, and compliance was good. The results show a beneficial effect on the nocturnal voids and sleep quality of women with OAB. Bryophyllum 50% tablets can be regarded as a well-tolerated alternative in the treatment of nocturia and broaden the repertoire of standard management.

show abstract

“…Nocturia is one of the most common and bothersome lower urinary tract symptoms and is the most common among the cohort of genitourinary symptoms attributed to menopause and the impact on the quantity of sleep, resulting in negative effects on overall health and decreased quality of life (QoL) [1,2]. The most widely used treatments currently available include three main pharmacological categories: desmopressin, nonselective and M3-selective antimuscarinic, and β3-adrenoreceptor agonist drugs [3].…”

Section: Introductionmentioning

confidence: 99%

Role of Protopine and Nuciferine in the Management of Nocturia, Urgency, and Dysuria in Pre- and Postmenopausal Women: A Prospective Pilot Study

Plotti

Silvagni

Cundari

et al. 2022

Gynecol Obstet Invest

View full text Add to dashboard Cite

Objectives: Nocturia was commonly treated with drugs burdened with high costs and numerous side effects; in fact, more than 70% of patients drop out of long-term treatment. Protopine and Nuciferine are two alkaloids that have different effects on the neurotransmitter receptors involved in the regulation mechanism of the onset of urinary stimuli. The aim of the study is to evaluate the efficacy in controlling primarily nocturia and secondarily urgency and dysuria after three months of treatment with combination therapy of protopine and nuciferine syrup. Design: This is a prospective cohort study in which all patients were diagnosed with overactive bladder syndrome (OAB) and the presence of symptoms: nocturia, urgency, and dysuria. 30 patients are administered 10 ml/die (16.6 mg of Nuciferine – 0.09 mg of Protopine) of syrup for 3 months. Patients are evaluated at baseline (T0) with the ICIQ questionnaire (International Consultation on Incontinence), VAS (Visual Analogue Scale) for the evaluation of dysuria, PPIUS (Patient Perception of Intensity of Urgency Scale) and at 3 months (T1) with the PGI-C Scale (Patients' Global Impression of Change), PPIUS, VAS and ICIQ. Participants: Women with diagnosis of OAB; presence of nocturia, urgency, and dysuria symptoms agreeing to undergo treatment and compiling informed consent; absence of contraindications to the use of active ingredients. Setting: Patients were recruited at (T0) during the visit to the Uro-Gynecology clinic of the University of 'Campus Bio-Medico' and visited again 3 months (T1) after the initiation of therapy. Methods: We explored survey data by descriptive statistics: in particular, continuous values (i.e., ICIQ) have been summarized by mean and standard deviation, discrete ordinal values (i.e., VAS, PPIUS, and bladder diary parameters at T0 and T1) by median, minimum, and maximum reported scores. Where we could assume normality in distribution, assessed by the Shapiro-Wilk test and the evaluation of the QQ plot, we compared the observation T0 and T1 with the paired Student's t test, otherwise we tested differences in distribution with the paired Mann–Whitney U test. Results: Thirty patients completed a three-month therapy. The ICIQ, VAS questionnaires for the assessment of dysuria, both, reported an improvement in dysuria at T1 (p< 0.001). The PPIUS questionnaire reported an improvement in urinary urgency in T1 (p<0.001). The PGI-C scale in T1 indicated an improvement in symptoms: 93% for nocturia, 70% for urinary urgency, and 63% for dysuria. Limitations: The weaknesses are the small number of patients, as a pilot study, the study design is not randomized with placebo and without blinding and the short follow-up. Conclusions: Protopine and Nuciferine can be an interesting alternative to primarily treat and reduce nocturia episodes, in addition to improving OAB-related urgency and dysuria. (Prot. N. Proto-Gyn-Uro 007/06.02.2019)

show abstract

Characterizing nocturia among Belgian healthy postmenopausal women: Prevalence, degree of bother, etiology and risk factors for nocturia

Cited by 6 publications

References 31 publications

Nocturia through the menopausal transition and beyond: a narrative review

Nocturia through the menopausal transition and beyond: a narrative review

Bryophyllum pinnatum and Improvement of Nocturia and Sleep Quality in Women: A Multicentre, Nonrandomised Prospective Trial

Role of Protopine and Nuciferine in the Management of Nocturia, Urgency, and Dysuria in Pre- and Postmenopausal Women: A Prospective Pilot Study

Contact Info

Product

Resources

About